Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents

Abstract Background SARS-CoV-2 vaccination has reduced hospitalization and mortality for nursing home residents (NHRs). However, emerging variants coupled with waning immunity, immunosenescence, and variability of vaccine efficacy undermine vaccine effectiveness. We therefore need to update our understanding of the immunogenicity of the most recent XBB.1.5 monovalent vaccine to variant strains among NHRs.Methods The current study focuses on a subset of participants from a longitudinal study of consented NHRs and HCWs who have received serial blood draws to assess immunogenicity with each SARS-CoV-2 mRNA vaccine dose. We report data on participants who received the XBB.1.5 monovalent vaccine after FDA approval in Fall 2023. NHRs were classified based on whether they had an interval SARS-CoV-2 infection between their first bivalent vaccine dose and their XBB.1.5 monovalent vaccination.Results The sample included 61 NHRs [median age 76 (IQR 68-86), 51% female] and 28 HCWs [median age 45 (IQR 31-58), 46% female). Following XBB.1.5 monovalent vaccination, there was a robust geometric mean fold rise (GMFR) in XBB.1.5-specific neutralizing antibody titers of 17.3 (95% confidence interval [CI] 9.3, 32.4) and 11.3 (95% CI 5, 25.4) in NHRs with and without interval infection, respectively. The GMFR in HCWs was 13.6 (95% CI 8.4,22). Similarly, we noted a robust GMFR in JN.1-specific neutralizing antibody titers of 14.9 (95% CI 7.9, 28) and 6.5 (95% CI 3.3, 13.1) among NHRs with and without interval infection, and a GMFR of 11.4 (95% CI 6.2, 20.9) in HCWs. NHRs with interval SARS-CoV-2 infection had higher neutralizing antibody titers across all analyzed strains following XBB.1.5 monovalent vaccination, compared to NHRs without interval infection.Conclusion The XBB.1.5 monovalent vaccine significantly elevates Omicron-specific neutralizing antibody titers to XBB.1.5 and JN.1 strains in both NHRs and HCWs. This response was more pronounced in individuals known to be infected with SARS-CoV-2 since bivalent vaccination.Impact Statement All authors certify that this work entitled “Broad immunogenicity to prior strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents” is novel. It shows that the XBB.1.5 monovalent vaccine significantly elevates Omicron-specific neutralizing antibody titers in both nursing home residents and healthcare workers to XBB and BA.28.6/JN.1 strains. This work is important since JN.1 increased from less than 0.1% to 94% of COVID-19 cases from October 2023 to February 2024 in the US. This information is timely given the CDC’s latest recommendation that adults age 65 and older receive a Spring 2024 XBB booster. Since the XBB.1.5 monovalent vaccine produces compelling immunogenicity to the most prevalent circulating JN.1 strain in nursing home residents, our findings add important support and rationale to encourage vaccine uptake.Key Points <jats:list list-type="bullet">Emerging SARS-CoV-2 variants together with waning immunity, immunosenescence, and variable vaccine efficacy reduce SARS-CoV-2 vaccine effectiveness in nursing home residents.XBB.1.5 monovalent vaccination elicited robust response in both XBB.1.5 and JN.1 neutralizing antibodies in nursing home residents and healthcare workers, although the absolute titers to JN.1 were less than titers to XBB.1.5Why does this paper matter? Among nursing home residents, the XBB.1.5 monovalent SARS-CoV-2 vaccine produces compelling immunogenicity to the JN.1 strain, which represents 94% of all COVID-19 cases in the U.S. as of February 2024..

Medienart:	Preprint

Erscheinungsjahr:	2024
Erschienen:	2024

Enthalten in:	bioRxiv.org - (2024) vom: 02. Apr. Zur Gesamtaufnahme - year:2024

Sprache:	Englisch

Beteiligte Personen:

Abul, Yasin [VerfasserIn] Nugent, Clare [VerfasserIn] Vishnepolskiy, Igor [VerfasserIn] Wallace, Tiffany [VerfasserIn] Dickerson, Evan [VerfasserIn] Holland, Laurel [VerfasserIn] Esparza, Iva [VerfasserIn] Winkis, Mandi [VerfasserIn] Wali, Kazi Tanvee [VerfasserIn] Chan, Philip A. [VerfasserIn] Baier, Rosa R. [VerfasserIn] Recker, Amy [VerfasserIn] Kaczynski, Matthew [VerfasserIn] Kamojjala, Shreya [VerfasserIn] Pralea, Alexander [VerfasserIn] Rice, Hailee [VerfasserIn] Osias, Olubunmi [VerfasserIn] Oyebanji, Oladayo A. [VerfasserIn] Olagunju, Olajide [VerfasserIn] Cao, Yi [VerfasserIn] Li, Chia Jung [VerfasserIn] Roederer, Alex [VerfasserIn] Pfeifer, Walther M. [VerfasserIn] King, Christopher L. [VerfasserIn] Bosch, Jurgen [VerfasserIn] Nanda, Aman [VerfasserIn] McNicoll, Lynn [VerfasserIn] Mujahid, Nadia [VerfasserIn] Raza, Sakeena [VerfasserIn] Tyagi, Rohit [VerfasserIn] Wilson, Brigid M. [VerfasserIn] White, Elizabeth M. [VerfasserIn] Canaday, David H. [VerfasserIn] Gravenstein, Stefan [VerfasserIn] Balazs, Alejandro B. [VerfasserIn]

Links:	Volltext [kostenfrei]

Themen:	570 Biology

doi:	10.1101/2024.03.21.24303684

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	XBI043039502